RESULTS :Efficacy and safety were assessed in 104 patients. The median time from first dose to data cutoff was 45.1 months (range, 41.3-49.3). Objective response rate was 18.3% (95% CI: 11.4-27.1), and median duration of response was 21.0 months (range, 3.1 to 39.5+). Disease control...
免疫检查点抑制剂纳武利尤单抗(Nivolumab)是首个获FDA批准的HCC免疫治疗药物,用于索拉非尼治疗失败的HCC二线治疗。另一个免疫检查点抑制剂帕博利珠单抗(Pembrolizumab),基于II期临床试验KEYNOTE-224的研究结果,FDA加速批准了帕博利珠单抗用于索拉非尼治疗后HCC患者的二线治疗。今年ASCO大会上最新公布了帕博利珠单抗的几项临...
We read every piece of feedback, and take your input very seriously. Include my email address so I can be contacted Cancel Submit feedback Saved searches Use saved searches to filter your results more quickly Cancel Create saved search Sign in Sign up Reseting focus {...
Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study 297 Background: Results from cohort 1 of KEYNOTE-224, an open-label, single-arm, multi-country phase II trial, demonstrated that pembro monotherapy was eff... JLV Laeth...
We read every piece of feedback, and take your input very seriously. Include my email address so I can be contacted Cancel Submit feedback Saved searches Use saved searches to filter your results more quickly Cancel Create saved search Sign in Sign up Reseting focus {...
results in Merkel cell polyomavirus (MCPyV)-negative MCC patients with TMB-H, while pembrolizumab therapy has shown better response in patients with low ... A Fojnica,K Ljuca,S Akhtar,... - 《Cancers》 被引量: 0发表: 2023年 加载更多来源...
Wu, ARRK Engineering Simulation Data Management from CAD to Results with LoCo and CAViT for Large Scale LS-DYNA® LEGO® Crash Models, M. Thiele, SCALE Cross-Platform Co-Simulation for Vehicle Safety Analysis, X. Tong, Ansys Challenges of simulative consideration of aluminium hardening caused...
At least with PPT windowed mode, there's only one minimal title bar across the top. But, of course, for those of us who've done this, the conversion from Keynote to PPT doesn't always execute... err, with the proper and intended results. Builds and animations don't always work, ...
Results Efficacy is reported in the table. Gr 3-5 drug-related AE rates with P vs E were 28.6% vs 76.9% in the Asia subgrp and 13.9% vs 67.2% in the non-Asia subgrp; rates with P+C vs E were 71.9% vs 76.9% in the Asia subgrp and 70.8% vs 67.2% in the non-Asia subgrp...
2017年美国FDA基于单臂Ⅱ期临床研究KEYNOTE-224的结果,附条件批准帕博利珠单抗用于肝癌的二线治疗。但在此之后,多个国际多中心的Ⅲ期临床研究均未达预设终点。 考虑到欧美国家与中国肝癌特征的差异,中国专家建议分开东、西方人群,分别开展两项临床研究,KEYNOTE-394研究应运而生。KEYNOTE-394对研究终点、样本量、统计方...